Main Article Content
Abstract
Numerous observational studies conducted in the past few years have confirmed the link between statin use and colorectal cancer by preserving and lowering the death rate. Statins may have an impact on cancer cells' ability to proliferate, migrate, and survive. Since the 1990s, the idea of utilizing statins to treat cancer has gained traction. Statins have been used in cohort studies, in vitro and in vivo tests, and on tumor-related inflammation and oxidative stress to show their anticancer effects. Method: we systematically searched for studies about the statin used in colorectal cancer patients in electronic databases, including PubMed, Web of Science, academic Google Scholar, and science direct, covering the last eight years up until 2022. A total of 8 studies, which include 506,346 individuals, of whom, 100,225 were statins users. The collected data assessed by using Statistical Package for the Social Sciences (SPSS). Result: Our analysis selected studies presented with outcome based on relative ratios (RRs) and 95% confidence intervals (CIs) of colorectal cancer-specific mortality. The use of statin was potentially associated with a decline in colorectal cancer-specific mortality in cancer patients (RR; 0.92; 95% CI, 0.90 to 0.95; random-effects model: RR0.90; 95% CI, 0.79 to 0.96). The meta-analysis showed that ongoing statin therapy was associated with a 20% decrease in the risk of colorectal cancer-specific mortality compared to patients without ongoing statin therapy (adjusted HR 0.75, 95%CI 0.65-0.85, P < .002). Conclusion: The risk of colorectal cancer was lower in statin user versus nonuser, accumulating evidence suggests that statins may have a role in colorectal cancer prevention and treatment. Among Lipid lowering medication (LLM) users, adherence to this drug is associated with a decrease in cancer-specific mortality.